AI Insight
Researchers tested whether weak inhibition of mitochondrial complex I (mtCI) using a small molecule called CP2 could improve symptoms in a mouse model of schizophrenia (mice carrying four copies of the Gldc gene). After 8 weeks of treatment, CP2 reversed multiple behavioral deficits, including impaired spatial memory, reduced startle habituation, and social novelty deficits. At the molecular level, CP2 restored expression of PGC-1alpha, a key regulator of mitochondrial biogenesis, and VDAC1, a protein involved in mitochondrial metabolite exchange, suggesting the behavioral improvements are linked to restored mitochondrial function.
Why it matters
Current antipsychotic medications primarily target dopamine and serotonin pathways and have significant limitations, so identifying mitochondrial function as a therapeutic target could open a new avenue for treating schizophrenia. If these findings translate to humans, compounds like CP2 could represent a mechanistically distinct treatment strategy for a condition affecting approximately 24 million people worldwide.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Weak inhibition of mitochondrial complex I (mtCI) has been shown to have neuroprotective effects in cellular and animal models of Alzheimers and Huntingtons diseases, at least in part by enhancing mitochondrial biogenesis and function. Mitochondrial dysfunction has also been demonstrated in schizophrenia patients and mouse models of schizophrenia. We tested whether weak inhibition of mtCI would ameliorate mitochondrial and behavioral phenotypes in a mouse model of schizophrenia. In mice with four copies of the Gldc gene, 8 weeks of treatment with the weak mtCI inhibitor, the small-molecule tricyclic pyrone compound CP2, reversed spontaneous alternation deficits in the Y maze, startle habituation deficits, and social novelty deficits in the three-chamber social interaction test. Consistent with the mechanism of action, Western blots revealed that CP2 reverses the reduced expression of PGC-1alpha, a master regulator of mitochondrial biogenesis, and of the VDAC1, a primary gatekeeper for the exchange of metabolites, ions, and ATP between mitochondria and the cytosol. These findings suggest that the improvement of mitochondrial function may represent a novel strategy to reverse pathophysiological and behavioral deficits in schizophrenia.